Loading
Hospitals in Spain make their own CAR-T for a third of the commercial price. Paying for such products at cost gives health systems a lever in negotiating with companies.
ARI-0001 and similar academic products are reimbursed in Spain under the hospital exemption at a fraction of commercial list prices, and published outcomes are comparable in matched populations. The proposal is for other public payers to establish explicit coverage of academic point-of-care CAR-T at audited cost plus a fixed margin, publish that cost, and use it as the reference price in negotiations for commercial products in the same indication, creating a competitive benchmark that does not otherwise exist for single-source therapies.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Manufacturing cost and time for living and radioactive medicines, Prices and value, CAR-T cell therapy.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value, CAR-T cell therapy.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.